JP2013532176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532176A5 JP2013532176A5 JP2013519027A JP2013519027A JP2013532176A5 JP 2013532176 A5 JP2013532176 A5 JP 2013532176A5 JP 2013519027 A JP2013519027 A JP 2013519027A JP 2013519027 A JP2013519027 A JP 2013519027A JP 2013532176 A5 JP2013532176 A5 JP 2013532176A5
- Authority
- JP
- Japan
- Prior art keywords
- fviii variant
- recombinant fviii
- amino acid
- recombinant
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 21
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 21
- 238000000338 in vitro Methods 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000009881 electrostatic interaction Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169592.2 | 2010-07-15 | ||
| EP10169592 | 2010-07-15 | ||
| US36547810P | 2010-07-19 | 2010-07-19 | |
| US61/365,478 | 2010-07-19 | ||
| PCT/EP2011/061349 WO2012007324A2 (en) | 2010-07-15 | 2011-07-06 | Stabilized factor viii variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013532176A JP2013532176A (ja) | 2013-08-15 |
| JP2013532176A5 true JP2013532176A5 (enExample) | 2014-08-21 |
Family
ID=42797590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519027A Ceased JP2013532176A (ja) | 2010-07-15 | 2011-07-06 | 安定化させた第ｖｉｉｉ因子バリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20130183280A1 (enExample) |
| EP (1) | EP2593130A2 (enExample) |
| JP (1) | JP2013532176A (enExample) |
| CN (1) | CN102971006A (enExample) |
| WO (1) | WO2012007324A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CN108530543B (zh) | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| CN102741275B (zh) | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| PL2718322T3 (pl) * | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| WO2013160005A1 (en) * | 2012-04-24 | 2013-10-31 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| JP2015533152A (ja) | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第ｖｉｉ因子コンジュゲート |
| UY35343A (es) * | 2013-02-26 | 2014-09-30 | Bayer Healthcare Llc | Formulaciones y procedimientos para la producción de proteína recombinante aumentada |
| LT3013855T (lt) | 2013-06-24 | 2021-01-25 | Xiao, Weidong | Mutavusio viii faktoriaus kompozicijos ir metodai |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| CN105637088A (zh) | 2013-10-15 | 2016-06-01 | 诺和诺德保健股份有限公司 | 凝固因子vii多肽 |
| US20160252519A1 (en) * | 2013-10-18 | 2016-09-01 | Dr. Reddy's Laboratories Limited | In-vitro method for determining fate of polypeptide variant |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| JP6516829B2 (ja) | 2014-08-04 | 2019-05-22 | シーエスエル、リミテッド | 第ｖｉｉｉ因子製剤 |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| WO2021084276A2 (en) * | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii construct |
| EP4058049A1 (en) | 2019-11-11 | 2022-09-21 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| WO2022063887A1 (en) * | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TR200101751T2 (tr) | 1998-04-28 | 2002-05-21 | Applied Research Systems Ars Holding N.V. | Poliol-IFN-beta konjugatları |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| EP2042196B1 (en) | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| WO2006102652A2 (en) | 2005-03-24 | 2006-09-28 | Neose Technologies, Inc. | Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms |
| WO2006103298A2 (en) * | 2005-04-01 | 2006-10-05 | Novo Nordisk Health Care Ag | Blood coagulation fviii analogues |
| WO2006134173A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| WO2006134174A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Dimeric and multimeric fviia compound |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| KR20080108147A (ko) * | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| US20080242607A1 (en) * | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| DK2257311T3 (da) | 2008-02-27 | 2014-06-30 | Novo Nordisk As | Konjugerede Faktor VIII-Molekyler |
| JP5785872B2 (ja) * | 2008-10-17 | 2015-09-30 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 低度の水溶性ポリマーを含む改変血液因子 |
-
2011
- 2011-07-06 US US13/808,204 patent/US20130183280A1/en not_active Abandoned
- 2011-07-06 EP EP11735405.0A patent/EP2593130A2/en not_active Withdrawn
- 2011-07-06 CN CN2011800348298A patent/CN102971006A/zh not_active Withdrawn
- 2011-07-06 JP JP2013519027A patent/JP2013532176A/ja not_active Ceased
- 2011-07-06 WO PCT/EP2011/061349 patent/WO2012007324A2/en not_active Ceased
-
2016
- 2016-06-01 US US15/170,502 patent/US20160264645A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | Functionalization of graphene oxide generates a unique interface for selective serum protein interactions | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| WO2009087082A3 (de) | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil | |
| AR119682A2 (es) | Composiciones inmunogénicas de antígenos de staphylococcus aureus | |
| RU2019124678A (ru) | Слитый белок pd1-41bbl и способы его применения | |
| CR11561A (es) | Proteinas de union a antigenos | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| MA37983A1 (fr) | Analogues du glucagon | |
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| HRP20220214T1 (hr) | Imunomodulacijska sredstva | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| CR20210076A (es) | Composiciones de anticuerpo fcrn | |
| IN2012DN03368A (enExample) | ||
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| NZ705384A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| IN2014KN01713A (enExample) | ||
| WO2011036443A3 (en) | Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders | |
| ES2675847T3 (es) | Nuevo anticuerpo anti-DR5 | |
| JP2012115277A5 (enExample) | ||
| WO2012018767A3 (en) | Antibodies directed against il-17 |